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ABSTRACT
Moloney murine leukaemia virus (M-MuLV) is a member of the retrovirus family. Its cloned reverse 
transcriptase (RT), similarly to HIV type 1 reverse transcriptase (HIV-1 RT), exhibits DNA-polymerase 
and ribonuclease H (RNase H) activities capable of converting the single-stranded retroviral RNA 
genome into double-stranded DNA. The latter is then integrated into the host chromosome during 
viral infection. M-MuLV RT is, therefore, an attractive enzyme to help understand mutations in HIV-
1 RT and its use in inhibition studies can help facilitate new drug designs. In this study, conjugates 
consisting of N-trityl derivatives of p-fluoro, p-nitro and p-iodo-DL-phenylalanine were coupled to 
8-(6-aminohexyl) amino-adenosine-3’,5’-cyclic monophosphate and examined for their effect on 
DNA synthesis by M-MuLV RT. Synthesis was studied in a system containing poly (rA).oligo d(pT)15 
as a template-primer with [3H] dTTP. The iodo-derivative, N-trityl-p-iodo-DL-phenylalanine-8-(6-
aminohexyl) amino-adenosine-3’,5’-cyclic monophosphate was found to be a very active inhibitor 
of the RT enzyme (IC50 = 1 µM), while the p-nitro (IC50 = 45 µM) and p-fluoro (IC50 = 65 µM) were 
weak inhibitors. Further work will be aimed at determining the mode of binding of the N-tritylated 
conjugates and also of various substituted amino acids and short peptides to M-MuLV RT to 
elucidate the mechanisms of inhibition.
INTRODUCTION
In a recent article1 we described the synthesis of a number of N-acylated derivatives of 8-(6-aminohexyl) 
amino-adenosine-5’-monophosphate. These various acylated derivatives, as well as the free N-trityl 
substituted DL-phenylalanyl amino acids, were tested for their effect on the DNA polymerase activity of 
the Moloney murine leukaemia virus reverse transcriptase (M-MuLV RT). A number of these compounds 
inhibited the enzyme with IC50 values (the concentration at which 50% inhibition of activity occurs) 
of 60 µM – 100 µM. If one particular compound, N-trityl-m-fluoro-DL-phenylalanine, was attached to 
the nucleotide 8-(6-aminohexyl) amino-adenosine-5’-monophosphate (Figure 1), the inhibitory activity 
increased, giving an IC50 value of 5 µM.
M-MuLV RT is a cloned enzyme expressed in Escherichia coli as a single polypeptide (71 kDa) 2 and, 
similarly to HIV type 1 reverse transcriptase (HIV-1 RT), exhibits both DNA-polymerase and ribonuclease 
H (RNase H) activities3; the common properties of M-MuLV RT and HIV-1 RT suggest that the two 
enzymes are able to carry out identical biological functions as far as the mechanism of DNA synthesis 
is concerned. Furthermore, the amino acid sequences of several drug-resistant mutations of HIV-1 RT 
have revealed similarities to the native sequences found in the M-MuLV RT catalytic fragment,4 which 
makes M-MuLV RT an attractive enzyme to help understand mutations in HIV-1 RT and its use in 
inhibition studies can help facilitate new drug designs.
In our previous paper,1 we made the assumption that the nucleotide component (5’-AMP) of the 
conjugate N-trityl-m-fluoro-DL-phenylalanine-8-(6-aminohexyl) amino-adenosine-5’-monophosphate 
could possibly bind to the polymerase site (area) of M-MuLV RT, while the N-trityl-m-fluoro-DL-
phenylalanine grouping was likely to interact with a hydrophobic pocket or area situated 10 Å – 15 Å 
away. The binding of the conjugate therefore resembled the interaction of certain chimeras with HIV-1 
FIGURE 1
Structure of N-trityl-m-fluoro-DL-phenylalanine-8-(6-aminohexyl) amino-adenosine-5’-monophosphate
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RT. We now realise that the suggested binding of the N-trityl 
conjugates mentioned above may have been entirely wrong and 
that other areas or sites on the RT enzyme may possibly have 
been involved (see Discussion). 
It was therefore of particular interest to see if replacement 
of the nucleotide adenosine-5’-phosphate component of 
N-trityl-p-substituted-DL-phenylalanine-8-(6-aminohexyl) 
amino-adenosine-5’-monophosphate by adenosine-3’,5’-cyclic 
monophosphate would result in inhibitory derivatives against 
the reverse transcriptase. This paper outlines the synthesis of 
three compounds containing 8-(6-aminohexyl) amino-adenosine-
3’,5’-cyclic monophosphate that are linked to different N-trityl-
p-substituted-DL-phenylalanines (p-fluoro, p-nitro and p-iodo; 
Figure 2) and their effects on the DNA polymerase activity of 
M-MuLV RT.
It would have been logical to use m-derivatives (m-fluoro, m-nitro 
and m-iodo) of DL-phenylalanine in these new conjugates 
with 3’,5’-cyclic-AMP. Our reason for using the N-tritylated-
p-substituted DL-phenylalanine derivatives was that we had 
adequate amounts of crystalline N-hydroxysuccinimide-
activated esters of these N-tritylated-p-substituted amino acids, 
while the m-substituted derivatives were not available.
MATERIALS AND METHODS
Poly (rA) and 8-(6-aminohexyl) amino-adenosine-3’,5’-cyclic 
monophosphate were supplied by Sigma (St Louis, United States 
of America). Oligo d(pT)15 and M-MuLV RT were supplied by 
Roche (Mannheim, Germany). The [3H] dTTP (65.5 Ci/mmol) 
used as the tetrasodium salt was obtained from American 
Radiolabeled Chemicals (St Louis, USA). All other chemical 
reagents were of analytical grade. 
We synthesised three new conjugates, as detailed below. 
The N-tritylated amino acids used were N-trityl-p-fluoro-DL-
phenylalanine, N-trityl-p-nitro-DL-phenylalanine and N-trityl-
p-iodo-DL-phenylalanine. The N-tritylated phenylalanines were 
activated as their N-hydroxysuccinimide derivatives, which were 
then coupled to 8-(6-aminohexyl) amino-adenosine-3’,5’-cyclic 
monophosphate (Figure 2). N-trityl-p-fluoro-DL-phenylalanine, 
N-trityl-p-nitro-DL-phenylalanine and N-trityl-p-iodo-DL-
phenylalanine were prepared as described previously by Nel 
and Ariatti5, using the method of Zervas and Theodoropoulos6. 
The N-hydroxysuccinimide derivatives of the above compounds 
were prepared according to the procedure of Nel and Ariatti5.
Assay for RNA-dependent DNA polymerase 
activity of M-MuLV RT
The incubation system contained 50 mM Tris-HCl (pH 8.3), 
20 mM KCl, 10 mM dithiothreitol, 5 mM MgCl
2
, reverse 
transcriptase (10 units), poly rA (1.0 µg), d(pT)15 primer 
(0.1 µg), [3H] dTTP (1.25 µCi) and dTTP (0.5 µg), in a final volume of 
20 µL. Reactions were carried out at 37 °C. Aliquots (4 µL) were 
removed at regular 1 min intervals after commencing the run 
and mixed into 20 µL 0.1 M EDTA (pH 7.0). From these solutions, 
aliquots (7 µL), were removed and streaked onto discs of DE-81 
paper, dried at 37 °C and then placed in 0.5 M sodium phosphate 
(pH 6.8) for 5 min. This procedure was repeated with fresh 
0.5 M phosphate. Discs were dried at 60 °C and radioactivity was 
assessed by liquid scintillation. Test compounds were dissolved 
in ethanol or 0.05 M Tris-HCl (pH 7.6). The final concentration of 
ethanol in test runs and controls was 10% (v/v).
N-trityl-p-fluoro-DL-phenylalanine-8-(6-aminohexyl) 
amino-adenosine-3’,5’-cyclic monophosphate
To a solution of 8-(6-aminohexyl) amino-adenosine-3’,5’-cyclic 
monophosphate (4.7 mg, 0.01 mmol) in 0.8 mL pyridine:H
2
O 
(1) Coupling of N-trityl amino acids to 8-(6-aminohexyl) amino-adenosine-3’,5’-cyclic monophosphate. 
(2) The N-trityl amino acids were activated as their N-hydroxysuccinimide derivatives.
(3) N-trityl-p-fluoro-DL-phenylalanine-8-(6-aminohexyl) amino-adenosine-3’,5’-cyclic monophosphate. 
(4) N-trityl-p-nitro-DL-phenylalanine-8-(6-aminohexyl) amino-adenosine-3’,5’-cyclic monophosphate. 
(5) N-trityl-p-iodo-DL-phenylalanine-8-(6-aminohexyl) amino-adenosine-3’,5’-cyclic monophosphate. 
Tr, trityl; equivalent to (C6H5)3-C-
FIGURE 2
Coupling of N-trityl amino acids to 8-(6-aminohexyl) amino-adenosine-3’,5’-cyclic monophosphate 
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(7:3, v/v) was added to the N-hydroxysuccinimide ester of 
N-trityl-p-fluoro-DL-phenylalanine (5.3 mg, 0.01 mmol) in 
0.4 mL pyridine:H
2
O (7:3, v/v). The reaction mixture was left in 
the dark at room temperature (20 °C) for 20 h. It was then taken 
to dryness under a stream of nitrogen at 30 °C. Traces of pyridine 
were removed by co-evaporation with toluene using nitrogen. 
The crude product was dissolved in 0.8 mL dioxane:ethanol:H
2
O 
(2:2:1, v/v) at 30 °C and chromatographed on silica gel 60 F254 
plates (20 cm × 20 cm) using CHCl
3
:CH
3
OH (4:1, v/v). The strongly 
absorbing UV band in the area around the origin was extracted 
with ethanol (7.0 mL) at 30 °C and filtered through Whatman 
No. 1 paper.
Chromatography of an aliquot of the filtered extract on silica 
gel 60 F254 using ethanol:H2O (5:1, v/v) produced a new single 
strongly absorbing UV spot (retardation factor [RF] = 0.6), which 
was positive for the trityl group (2% aqueous HClO
4
, 100 °C). 
The starting material 8-(6-aminohexyl) amino-adenosine-3’,5’-
cyclic monophosphate produced an RF value of 0.26, while 
N-hydroxysuccinimide had an RF value of 0.49. 
On UV examination, with ethanol as a solvent, the new compound, 
N-trityl-p-fluoro-DL-phenylalanine-8-(6-aminohexyl) amino-
adenosine-3’,5’-cyclic monophosphate, was found to have a 
maximum wavelength (λ
max
) of 274 nm and a 274/243 ratio of 
2.98. The mass spectrum of the compound was measured in 
methanol containing 0.1% formic acid. The precursor ion of the 
new compound had a molecular mass of 869.5 Da and product 
ions with mass-to-charge (m/z) ratios of 243.1 (trityl), 299.1, 353.3, 
381.4, 409.3, 537.4 and 627.1 were found.
N-trityl-p-nitro-DL-phenylalanine-8-(6-aminohexyl) 
amino-adenosine-3’,5’-cyclic monophosphate
This compound was prepared similarly to the method 
described above for the p-fluoro derivative. The synthesis used 
8-(6-aminohexyl) amino-adenosine-3’,5’-cyclic monophosphate 
(4.7 mg, 0.01 mmol) and the N-hydroxysuccinimide ester 
of N-trityl-p-nitro-DL-phenylalanine (5.6 mg, 0.01 mmol). 
Following isolation by thin layer chromatography (TLC), the 
final product was dissolved in ethanol, giving a single spot on 
TLC of RF = 0.71 using silica gel 60F254 and ethanol:H2O (5:1, v/v). 
With ethanol as a solvent, the UV had a λ
max
 of 274 nm, a 274/244 
ratio of 2.54 and a mass spectrum m/z of 245.1 (trityl), 299.2, 
333.3, 413.3, 671.5, and 879.6 (molecular mass = 879.6). 
N-trityl-p-iodo-DL-phenylalanine-8-(6-aminohexyl) 
amino-adenosine-3’,5’-cyclic monophosphate 
This compound was also similarly prepared as described above 
for the p-fluoro derivative. The synthesis used 8-(6-aminohexyl) 
amino-adenosine-3’,5’-cyclic monophosphate (4.7 mg, 0.01 
mmol) and the N-hydroxysuccinimide ester of N-trityl-p-iodo-
DL-phenylalanine (6.4 mg, 0.01 mmol). Following isolation by 
TLC, the pure derivative was dissolved in ethanol and gave a 
single spot on TLC (silica gel 60F254), with an RF of 0.78 using 
ethanol:H
2
O (5:1, v/v). With ethanol as a solvent, the UV had a 
λ
max
 of 273 nm and a 273/244 ratio of 2.13. When run in negative 
mode, the mass spectrum m/z ratios were 243.1 (trityl), 444.2, 
717.1, 734.6 and 960.3 (molecular mass = 960.5). In positive mode, 
the mass spectrum results showed m/z ratios of 442.1, 510.1, 957.1 
and 958.1 (molecular mass = 960.5).
RESULTS AND DISCUSSION
Previous work from our laboratory1 described the effects of 
various N-trityl amino acids, as well as the conjugate compound 
N-trityl-m-fluoro-DL-phenylalanine-8-(6-aminohexyl) amino-
adenosine-5’-monophosphate, on the activity of enzyme-MuLV 
RT (Figure 1). The N-tritylated amino acids all inhibited the 
reverse transcriptase with IC50 values varying between 95 µM 
and 65 µM. When N-trityl-m-fluoro-DL-phenylalanine was 
chemically coupled to the 6-amino-side chain of 8-(6-aminohexyl) 
amino-adenosine-5’-monophosphate, however, the resulting 
conjugate showed a dramatic increase in inhibitory activity, with 
an IC50 value of 5 µM; we have previously discussed possible 
reasons for this and also suggested how the conjugate might 
bind to the reverse transcriptase enzyme.1
In this study, we wished to examine whether the replacement 
of the adenosine-5’-monophosphate component of 
N-trityl-m-fluoro-DL-phenylalanine-8-(6-aminohexyl) amino-
adenosine-5’-monophosphate with 8-(6-aminohexyl) amino-
adenosine-3’,5’-cyclic monophosphate would result in a 
conjugate with an inhibitory effect on the reverse transcriptase 
enzyme. We therefore synthesised three new conjugates: N-trityl-
p-fluoro-DL-phenylalanine, N-trityl-p-nitro-DL-phenylalanine 
and N-trityl-p-iodo-DL-phenylalanine.
Assays for reverse transcriptase activity (reported as IC50 
values) were carried out using poly (rA)-d(pT)15 as the template-
primer and measuring incorporation of [3H]dTTP into newly 
synthesised DNA (poly dT)7 (Table 1). The p-iodo derivative 
was clearly a good inhibitor (IC50 = 1 µM), while the p-nitro 
(IC50 = 45 µM) and p-fluoro (IC50 = 65 µM) derivatives were weak 
inhibitors. The molecular/kinetic reasons for these differences are 
not apparent at present. It is worth noting that the 8-(6-aminohexyl) 
amino-adenosine-3',5'-cyclic monophosphate that was run as a 
control resulted in a weak inhibition of the reverse transcriptase 
enzyme (IC50 = 800 µM).
The strongly inhibitory activity of the p-iodo derivative 
is interesting; the iodine atom has a large radius 
(covalent radius = 1.33 Å) and is lipophilic, whilst fluorine and 
bromine have covalent radii of 0.72 Å and 1.14 Å, respectively. 
The large covalent radius of the iodine atom may have had some 
bearing on the activity of the nucleotide conjugate.
Cushman and colleagues8 synthesised a number of HIV-1 reverse 
transcriptase inhibitors, of which one of the most active was 
3’,3’’-dibromo-4’,4’’-dimethoxy-5’,5’’-bis(methoxycarbonyl)-1,1-
diphenyl-1-heptene. They reported that replacement of the two 
bromine atoms in the above compound with two chlorine atoms 
resulted in a compound with decreased HIV-1 RT inhibitory 
activity.
In this study, the compounds synthesised and evaluated as 
inhibitors of the M-MuLV RT were originally visualised as 
chimeras. Several other researchers9,10,11,12 originally suggested 
the idea of cross-linking a non-nucleoside compound, 
specifically a non-nucleoside reverse transcriptase inhibitor 
(NNRTI), to substrates (i.e. the formation of a chimera). 
As reported in our previous paper,1 the design features of the 
nucleotide-N-trityl-m-fluoro-DL-phenylalanine appear to be 
consistent with these ideas. The concept of chimera structures 
binding to M-MuLV RT was prominent in our thinking when 
we began to carry out the work reported in the present paper. 
We now believe that the evidence for a chimera-type inhibitor 
and the mechanism we proposed, that is, of conjugates binding 
to M-MuLV RT, is incorrect, for the reasons outlined below.
TABLE 1
The effect of different N-trityl-p-substituted DL-phenylalanine-8-(6-aminohexyl) 
amino-adenosine-3’,5’-cyclic monophosphates on DNA synthesis by 
Moloney murine leukaemia virus reverse transcriptase  
N-trityl derivatives IC50 (μM)
8-(6-aminohexyl) amino-adenosine-3’,5’-cyclic monophos-
phate
800
N-trityl-p-fluoro-DL-phenylalanine-8-(6-aminohexyl) amino-
adenosine-3’,5’-cyclic monophosphate
65
N-trityl-p-nitro-DL-phenylalanine-8-(6-aminohexyl) amino-
adenosine-3’,5’-cyclic monophosphate
45
N-trityl-p-iodo-DL-phenylalanine-8-(6-aminohexyl) amino-
adenosine-3’,5’-cyclic monophosphate
1
IC50, the concentration at which 50% inhibition of activity is achieved. 
The incubation system contained poly (rA)-d(pT)15 as the template-primer to measure [
3H]
dTTP incorporation into DNA.
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Binding of N-trityl-p-fluoro-DL-phenylalanine-
8-(6-aminohexyl) amino-adenosine-3’,5’-cyclic 
monophosphate and the p-nitro and p-iodo substituted 
DL-phenylalanine conjugates to M-MuLV RT 
HIV-1 RT is possibly the most extensively studied enzyme and a 
multitude of studies on its crystal structure have been reported.9,12 
Although there are distinct structural differences between the 
monomeric M-MuLV RT and the heterodimeric HIV-1 RT, it 
is important to keep in mind that the respective polymerase 
domains of M-MuLV RT and HIV-1 RT are approximately 
85% structurally similar.13,14 This similarity allows the use of 
M-MuLV-RT as a tool in order better to understand the reverse 
transcription process and the design of novel inhibitors for HIV-
1 RT. We do not know how the M-MuLV RT binds NNRTIs, 
whether there is a hydrophobic pocket present, or whether the 
inhibitor can induce allosteric changes in the enzyme structure. 
It is also unlikely that the nucleotide (5’-AMP or 3’,5’-cyclic-
AMP) component of the conjugate is binding near, or at, the 
polymerase site, as these are not deoxyribose nucleoside 
triphosphates but ribose-containing nucleotides. Also, inhibition, 
when it occurs, should be non-competitive. When using N-trityl-
m-fluoro-DL-phenylalanine-8-(6-aminohexyl) amino-adenosine-
5’-monophosphate in our original paper,1 we performed 
competition experiments using varying concentrations of poly 
rA, d(pT)16 at fixed concentrations of N-trityl-m-fluoro-DL-
phenylalanine-nucleotide, which showed the compound acted 
as a non-competitive inhibitor (results not published).
It is thus unlikely that the DL-phenyl conjugates would fit into 
both the polymerase binding area and the nearby allosteric 
pocket site. Based on our results, we propose that other areas of 
the M-MuLV RT enzyme are being used for the attachment and 
functioning of the N-tritylated conjugates.
A number of research groups have reported on the synthesis and 
biological evaluation of dimers, some of which behave as true 
chimeras.15,16,17,18,19 Velázquez et al.15,16 have prepared a number 
of dimers consisting of 3’-azido-2’,3’-dideoxy thymidine (AZT) 
linked to the non-nucleoside (NNRTI) TSAO or HEPT. These 
can be written as [AZT]-[TSAO-T] and [AZT]-[HEPT]. They 
can also be placed in a general formula: [ddN]-(CH
2
)n-[NNRTI], 
where n = 3–9.
The TSAO-T molecule does not bind in the hydrophobic pocket 
of the HIV-1 RT, but rather interacts with certain amino acids 
at the interface of the p51 and p66 subunits. Velázquez et al.15 
believe that the [AZT]-[TSAO-T] dimer works only through the 
NNRTI portion of the molecule and not through the AZT (ddN) 
segment. It should be noted that TSAO is also a ribose derivative. 
The [AZT]-(CH
2
)n-[TSAO-T] structure is shown in Figure 3.
A recent paper by Tomassi et al.20 deals with the synthesis of new 
TSAO-T derivatives, particularly TSAO-Boc3T. The introduction 
of a Boc grouping to the N-3 position of the thymidine ring 
creates a good inhibitor of HIV-1 RT activity. Besides details of 
the synthesis and biological evaluation of this inhibitor, they 
report on computational analysis regarding the binding site of 
the enzyme.20
Our further work will be aimed at determining the mode 
of binding of the N-tritylated conjugates and also of various 
substituted amino acids and short peptides to M-MuLV RT, in 
order to resolve the abovementioned uncertainties.
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